← Leaderboards
Karen Sandell Sfanos
Johns Hopkins University
$787,833
Attributed
$1,654,184
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $999.4K · FY2024–25$1M$750K$500K$250K$0
'24
'25
Funding mix
By agency
NIH$1,654,184 · 2
By mechanism
R01$1,654,184 · 2
Top collaborators
- Amy E Moran2 shared
- Jason Michael Ridlon2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Samuel R Denmeade$5,431,317
- Martin G Pomper$38,517,075
- Stefan David Baral$19,320,514
- Jun Luo$3,173,526
- William Nathaniel Brennen$3,292,142
Others in their field
Other Rising Stars on “Tumor”
- Kenneth Schultz · Trethera Corporation$7,146,643
- Jeff P Simko · Washington University$4,848,843
- Gary G Schwartz · University Of North Dakota$4,000,000
- Yicheng Wang · Immunova Therapeutics, Llc$4,000,000
- David G Brooks · Boston Immune Technologies And Therapeutics, Inc.$3,974,764
- Daniel Francis · Claria Medical, Inc.$3,708,259
Research focus
TumorPublishingMediatingTreatment ResponseAdvanced Prostate CancerReportingCohortMalignant NeoplasmsNeoplastic CellTargeted TreatmentChemotherapyTumor PromotionAndrogen TherapyCessation Of LifeAutomobile DrivingClinical TrialsImmuneMalignant Neoplasm Of ProstateAndrogen Independent Prostate CancerMetastatic Prostate CancerAntibiotic TherapyAndrogensCancer ModelAndrogen Receptor
Grant awards (3)
Defining the Mechanistic Basis of Bacterial Androgen Production in Dampening Anti-Tumor Immunity and Promoting Resistance to Androgen Receptor Axis-Targeted Therapies for Metastatic Prostate Cancer$644,763
R01 · FY2025 · CA · contact PI
Subclonal p27 Loss and Altered Tumor Immune Microenvironment as a Driver of Fatal Prostate Cancer$354,658
R01 · FY2025 · CA · contact PI
Defining the Mechanistic Basis of Bacterial Androgen Production in Dampening Anti-Tumor Immunity and Promoting Resistance to Androgen Receptor Axis-Targeted Therapies for Metastatic Prostate Cancer$654,763
R01 · FY2024 · CA · contact PI